ATE492642T1 - Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie - Google Patents

Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie

Info

Publication number
ATE492642T1
ATE492642T1 AT06017245T AT06017245T ATE492642T1 AT E492642 T1 ATE492642 T1 AT E492642T1 AT 06017245 T AT06017245 T AT 06017245T AT 06017245 T AT06017245 T AT 06017245T AT E492642 T1 ATE492642 T1 AT E492642T1
Authority
AT
Austria
Prior art keywords
gene therapy
dna molecule
circular dna
production process
replication origin
Prior art date
Application number
AT06017245T
Other languages
English (en)
Inventor
Joel Crouzet
Fabienne Soubrier
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9482580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE492642(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE492642T1 publication Critical patent/ATE492642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
AT06017245T 1995-09-15 1996-09-13 Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie ATE492642T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9510825A FR2738842B1 (fr) 1995-09-15 1995-09-15 Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE492642T1 true ATE492642T1 (de) 2011-01-15

Family

ID=9482580

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06017245T ATE492642T1 (de) 1995-09-15 1996-09-13 Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
AT96931124T ATE284966T1 (de) 1995-09-15 1996-09-13 Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
AT04016978T ATE352630T1 (de) 1995-09-15 1996-09-13 Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT96931124T ATE284966T1 (de) 1995-09-15 1996-09-13 Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
AT04016978T ATE352630T1 (de) 1995-09-15 1996-09-13 Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie

Country Status (20)

Country Link
US (3) US6977174B2 (de)
EP (3) EP1724354B1 (de)
JP (3) JP3818665B2 (de)
KR (1) KR100522369B1 (de)
AT (3) ATE492642T1 (de)
BR (1) BRPI9610511B8 (de)
CA (1) CA2229307C (de)
CZ (1) CZ294525B6 (de)
DE (3) DE69638314D1 (de)
DK (3) DK0850310T3 (de)
ES (3) ES2233975T3 (de)
FR (1) FR2738842B1 (de)
HU (1) HU224400B1 (de)
IL (4) IL123641A0 (de)
NO (1) NO323975B1 (de)
PT (3) PT1724354E (de)
SK (1) SK285317B6 (de)
TW (1) TWI231826B (de)
WO (1) WO1997010343A1 (de)
ZA (1) ZA967640B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7038026B2 (en) * 2000-05-26 2006-05-02 Centelion Purification of a triple heli formation with an immobilized oligonucleotide
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US6156574A (en) 1997-06-23 2000-12-05 The Rockefeller University Methods of performing gene trapping in bacterial and bacteriophage-derived artificial chromosomes and use thereof
US6821759B1 (en) 1997-06-23 2004-11-23 The Rockefeller University Methods of performing homologous recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US6022716A (en) 1998-04-10 2000-02-08 Genset Sa High throughput DNA sequencing vector
EP1100884A1 (de) * 1999-06-07 2001-05-23 Cell Genesys, Inc. Hefe-bakterien hybrid klonierungssystem sowie verwendungen
WO2001005962A1 (en) * 1999-07-20 2001-01-25 The Rockefeller University Conditional homologous recombination of large genomic vector inserts
FR2821855B1 (fr) † 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
FR2822476B1 (fr) 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US6989261B2 (en) 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7049121B2 (en) 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
FI116068B (fi) 2003-09-15 2005-09-15 Fit Biotech Oyj Plc Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
JP4581851B2 (ja) * 2004-07-27 2010-11-17 セイコーエプソン株式会社 電気光学装置の駆動回路及び駆動方法、電気光学装置並びに電子機器
ATE545701T1 (de) * 2005-05-17 2012-03-15 Ozgene Pty Ltd Sequentielles klonierungssystem
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2007041350A2 (en) * 2005-10-01 2007-04-12 Charles Stout Regulatable fusion promoters
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
EP2310500B1 (de) * 2008-07-18 2015-03-11 Maxcyte, Inc. Verfahren zur optimierung einer elektroporation
EP2221066A1 (de) 2009-02-18 2010-08-25 Sanofi-Aventis Verwendung des VgII3-Aktivitätsmodulators zur Modulierung von Adipogenese
ES2566553T3 (es) 2010-03-17 2016-04-13 Association Institut De Myologie ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares
US9403880B2 (en) 2010-11-26 2016-08-02 Institut Pasteur Identification of a human gyrovirus and applications
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
US9550998B2 (en) 2012-08-29 2017-01-24 Nature Technology Corporation DNA plasmids with improved expression
US20150322439A1 (en) 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
JP2016524590A (ja) * 2013-03-14 2016-08-18 エペイウス バイオテクノロジーズ コーポレイション 遺伝子療法適用のためのチミジンキナーゼ診断アッセイ
EP3456821B2 (de) 2017-09-19 2024-01-24 Deutsches Krebsforschungszentrum Nicht integrierende dna-vektoren zur genetischen modifikation von zellen
WO2019057774A1 (en) 2017-09-19 2019-03-28 Deutsches Krebsforschungszentrum NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS
AU2019240068B2 (en) 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
US12582726B1 (en) 2019-04-05 2026-03-24 Earli Inc. Synthetic cancer-specific promoters
EP3946470A4 (de) 2019-04-05 2023-05-31 Earli Inc. Verbesserte verfahren und zusammensetzungen für synthetische biomarker
CN118742645B (zh) * 2022-06-13 2025-07-15 南京金斯瑞生物科技有限公司 一种可提高无筛选标签质粒制备效率的野生型-突变体π蛋白切换表达系统
JP2025525583A (ja) * 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
EP4762185A1 (de) * 2023-08-18 2026-06-24 DNA Twopointo, Inc. Plasmid-wirt-systeme
CN122497758A (zh) 2024-01-25 2026-07-31 阿尔德夫隆有限责任公司 具有改进的生产性能的病毒和非病毒纳米质粒载体
TR2024004346A2 (tr) * 2024-04-05 2024-05-21 Yildiz Teknik Ueniversitesi Doener Sermaye Isletme Mued Fotodönüştürülebilir floresan gen ihtiva eden antimikrobiyal aktivite tayin kiti.
WO2025231315A2 (en) 2024-05-03 2025-11-06 Aldevron, L.L.C. Bacterial host strains
WO2026076187A1 (en) 2024-10-03 2026-04-09 Aldevron, L.L.C. Compositions and methods for microbial production of antibiotic-free closed-ended linear dna

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4654307A (en) * 1983-02-17 1987-03-31 The Research Foundation Of State University Of New York Novel bacteria containing a plasmid having a tRNA code
US4761367A (en) * 1984-11-07 1988-08-02 The University Of North Carolina At Chapel Hill Vectors suitable for detection of eukaryotic DNA regulatory sequences
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5198343A (en) * 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5510099A (en) * 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
JPH03187383A (ja) * 1989-09-04 1991-08-15 Takeda Chem Ind Ltd 発現プラスミドおよびその用途
EP0485701A1 (de) * 1990-09-28 1992-05-20 American Cyanamid Company Einfügen von DNS mittels abgewandelter Transposons
TW201794B (de) * 1991-05-03 1993-03-11 American Cyanamid Co
US5714323A (en) * 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
US5444149A (en) * 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
ES2178654T3 (es) * 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
IL109558A (en) * 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
EP0770130A1 (de) * 1994-07-08 1997-05-02 Schering Corporation METHODE ZUR IDENTIFIZIERUNG VON NUKLEINSÄUREN KODIEREND FÜR c-fos PROMOTER AKTIVIERENDE PROTEINE
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US5792647A (en) * 1995-02-13 1998-08-11 The Johns Hopkins University Bacterial catabolism of chitin
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US5763270A (en) * 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
FR2738842B1 (fr) * 1995-09-15 1997-10-31 Rhone Poulenc Rorer Sa Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique
US7279313B2 (en) * 1995-09-15 2007-10-09 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US7364894B2 (en) * 1995-09-15 2008-04-29 Centelion Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
US5874259A (en) * 1997-11-21 1999-02-23 Wisconsin Alumni Research Foundation Conditionally amplifiable BAC vector

Also Published As

Publication number Publication date
EP1724354A2 (de) 2006-11-22
ATE284966T1 (de) 2005-01-15
HUP9900018A1 (hu) 1999-04-28
ES2281721T3 (es) 2007-10-01
NO323975B1 (no) 2007-07-30
ZA967640B (en) 1997-03-25
EP1508620A1 (de) 2005-02-23
DK0850310T3 (da) 2005-04-25
NO981044D0 (no) 1998-03-10
CA2229307A1 (fr) 1997-03-20
EP1724354A3 (de) 2008-10-29
WO1997010343A1 (fr) 1997-03-20
EP0850310B1 (de) 2004-12-15
EP1724354B1 (de) 2010-12-22
AU6992496A (en) 1997-04-01
HUP9900018A3 (en) 2001-10-29
CZ294525B6 (cs) 2005-01-12
JP3818665B2 (ja) 2006-09-06
ES2233975T3 (es) 2005-06-16
BR9610511B1 (pt) 2010-10-19
FR2738842A1 (fr) 1997-03-21
CZ78898A3 (cs) 1998-06-17
IL173399A0 (en) 2006-06-11
ES2357098T3 (es) 2011-04-18
NO981044L (no) 1998-03-10
US6977174B2 (en) 2005-12-20
KR100522369B1 (ko) 2006-10-24
JP2000501281A (ja) 2000-02-08
DE69636878D1 (de) 2007-03-15
US20090130674A1 (en) 2009-05-21
CA2229307C (fr) 2013-06-11
TWI231826B (en) 2005-05-01
KR19990044683A (ko) 1999-06-25
US20010014476A1 (en) 2001-08-16
SK34798A3 (en) 1998-11-04
PT850310E (pt) 2005-05-31
SK285317B6 (sk) 2006-10-05
JP2007325603A (ja) 2007-12-20
BR9610511A (pt) 1999-01-26
MX9802005A (es) 1998-08-30
EP0850310A1 (de) 1998-07-01
IL123641A (en) 2006-06-11
HU224400B1 (hu) 2005-08-29
DE69634043T2 (de) 2005-08-18
IL123641A0 (en) 1998-10-30
DE69638314D1 (de) 2011-02-03
JP4756014B2 (ja) 2011-08-24
PT1508620E (pt) 2007-05-31
FR2738842B1 (fr) 1997-10-31
DK1508620T3 (da) 2007-05-29
JP2006136328A (ja) 2006-06-01
AU728231B2 (en) 2001-01-04
DE69634043D1 (de) 2005-01-20
IL207348A0 (en) 2010-12-30
ATE352630T1 (de) 2007-02-15
PT1724354E (pt) 2011-03-09
BRPI9610511B8 (pt) 2016-11-08
DE69636878T2 (de) 2007-11-08
US20090149406A1 (en) 2009-06-11
DK1724354T3 (da) 2011-04-04
IL173399A (en) 2010-11-30
JP4585435B2 (ja) 2010-11-24
EP1508620B1 (de) 2007-01-24

Similar Documents

Publication Publication Date Title
ATE352630T1 (de) Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
AU560340B2 (en) Rennin from recombinant dna
WO1996021007A3 (en) Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
EA199700364A1 (ru) Способ контроля силилирования протеинов, продуцируемых в культуре клеток млекопитающих
ATE298789T1 (de) Negativstrand rna virus mit selbständiger replikationsaktivität
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
ATE159297T1 (de) Expression von menschlichen serumalbumin in methylotrophischen hefen
AU1682092A (en) Production of plants resistant to attacks of sclerotinia sclerotiorum by introducing a gene coding for an oxalate oxidase
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
ES2078243T3 (es) Mejoras en o relativas a la expresion eucariotica.
JPS6427473A (en) Human pancreas-secreting trypsin inhibitor and production thereof
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
ES8405842A1 (es) Procedimiento de producir razas estables de celulas de mamiferos
RU94043698A (ru) СПОСОБ ПОЛУЧЕНИЯ ФЕРМЕНТА ДЕСТАБИЛАЗЫ, ОБЛАДАЮЩЕГО ФИБРИНОЛИТИЧЕСКОЙ, ТРОМБОЛИТИЧЕСКОЙ, ЭНДО- И ЭКЗО- Е( -glu)-Lys-ИЗОПЕПТИДАЗНОЙ И АМИДОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
AU6252294A (en) A mutant protein and methods and materials for making and using it
ATE288476T1 (de) Herstellung von proteinen
SE8903865D0 (sv) Expression of heterologous proteins using eukaryotic cells
SU1591484A1 (ru) Способ получения рекомбинантного альфа-2 интерферона человека
DE3688974D1 (de) Expressionssysteme zur überproduktion gewünschter proteine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1724354

Country of ref document: EP